Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01903330 · ClinicalTrials.gov registry record · Phase 2
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
A Phase 2 study of Glioblastoma and Gliosarcoma, sponsored by Epitopoietic Research Corporation.
- Active
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 3
- Study locations
NCT01903330: Active Phase 2 study of Glioblastoma and Gliosarcoma, sponsored by Epitopoietic Research Corporation.
NCT01903330 is a Phase 2 study of Glioblastoma and Gliosarcoma that is active but no longer recruiting, run by Epitopoietic Research Corporation. The registered enrollment target is 84 participants, below the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (22% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01903330, a Phase 2 study of Glioblastoma and Gliosarcoma, is active but no longer recruiting, sponsored by Epitopoietic Research Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II clinical trial studies how well ERC1671 plus Granulocyte-macrophage colony-stimulating factor (GM-CSF) plus Cyclophosphamide with Bevacizumab works compared to Placebo Injection plus Placebo Pill with Bevacizumab in treating patients with recurrent/progressive, bevacizumab naïve glioblastoma multiforme and gliosarcoma (World Health Organization (WHO) grade IV malignant gliomas, GBM).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG GM-CSF
- DRUG ERC1671
- DRUG Oral Control (Sucrose pill)
- DRUG Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))
Study Locations (3)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana Farber Cancer Institute - Boston
California
- University of California, Irvine - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2014-03 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What the registry record for NCT01903330 still lists
NCT01903330 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (22% lower).
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01903330 reports a single indexed study location in Massachusetts, California.
Frequently Asked Questions
What is clinical trial NCT01903330 about?
NCT01903330 is a clinical study titled "ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme". This phase II clinical trial studies how well ERC1671 plus Granulocyte-macrophage colony-stimulating factor (GM-CSF) plus Cyclophosphamide with Bevacizumab works compared to Placebo Injection plus Placebo Pill with Bevacizumab in treating patients with recurrent/progressive, bevacizumab naïve gliobl...
What is the current status of trial NCT01903330?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2014-03. Estimated completion is 2026-06.
What conditions does trial NCT01903330 study?
This clinical trial studies the following conditions: Glioblastoma, Gliosarcoma.
What interventions are being tested in trial NCT01903330?
The interventions under investigation include: Cyclophosphamide (DRUG), GM-CSF (DRUG), ERC1671 (DRUG), Oral Control (Sucrose pill) (DRUG), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)) (DRUG).
Who is sponsoring clinical trial NCT01903330?
This trial is sponsored by Epitopoietic Research Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01903330 being conducted?
This trial has 3 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01903330's enrollment target sits among peer trials
84 54th of 199 higher than 146 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia